Remembering Professor Paolo Pederzoli and His Legacy in Pancreatic Surgery
-
By
-
Roberto Salvia
-
October 16, 2026
Clinical Report: Remembering Professor Paolo Pederzoli and His Legacy
Overview
Professor Paolo Pederzoli was a pioneer of pancreatic surgery and an early advocate of multidisciplinary care for pancreatic disease. His legacy includes leadership of Italy’s first unit devoted exclusively to pancreatic diseases, contributions to research and training, and a patient-centered approach to care.
Background
Pancreatic disease requires expertise extending beyond operative technique, a principle reflected in the multidisciplinary model that developed in Verona during the 1990s. Pederzoli worked alongside specialists in internal medicine, gastroenterology, radiology, and pathology as this approach took shape. From 2002 to 2011, he led the University Hospital of Verona’s Unit of General and Pancreatic Surgery, described in the source as Italy’s first unit devoted exclusively to pancreatic diseases. His career also encompassed research, professional leadership, and the education of surgeons who continued this work in Verona and elsewhere.
Data Highlights
The source provides career dates and research areas but no numerical clinical-trial outcomes.
Key Findings
- Pederzoli headed Verona’s Unit of General and Pancreatic Surgery from 2002 to 2011 and helped establish the Verona pancreatic school.
- He was an early proponent of multidisciplinary management, working with specialists in internal medicine, gastroenterology, radiology, and pathology.
- His research collaborations included publications on pancreatic fistulas in the 1980s and investigations of acute necrotizing pancreatitis in the 1990s, including antibiotic prophylaxis, drainage, and lavage [1–4].
- His later work included pancreatic cancer surgery and lymphadenectomy; he also supported Verona’s participation in the International Cancer Genome Consortium.
- As president, he established and led the Italian Foundation for Research in Pancreatology (FIMP), which funded research projects and supported young investigators.
- The account describes his teaching as emphasizing guidance, confidence, and responsibility, and identifies attentive, humane patient relationships as central to his legacy.
Clinical Implications
The account presents Pederzoli’s work as an example of pancreatic care developed through collaboration across clinical and diagnostic specialties, alongside surgical training and research. It also emphasizes that his approach to patients included listening, sustained follow-up, warmth, and a sense of responsibility.
Conclusion
Pederzoli’s legacy, as described by his colleagues, spans multidisciplinary pancreatic care, research, education, and close relationships with patients. His influence continues through the Pancreas Institute in Verona and centers shaped by surgeons he trained.
Related Resources & Content
- Source article, Remembering Professor Paolo Pederzoli and His Legacy in Pancreatic Surgery, year not provided
- Obesity Surgery, In Memoriam: Professor Marian Pardela, Esteemed Polish Surgeon and Trailblazer in Bariatric Surgery, 2021
- Updates in Surgery, In Memoriam: Davide Francesco D’Amico (1936–2026), Pioneer of Hepatobiliary Surgery and Liver Transplantation, 2026
- The ASCO Post, A Love for Surgery Underpins a Career Devoted to Patients With Pancreatic Cancer, 2021
- Howard A. Reber, M.D.: Esteemed Surgical Professor at UCLA School of Medicine
- Multidisciplinary Tumor Board Documentation: Assessing its Frequency, Quality, and Impact | Annals of Surgical Oncology | Springer Nature Link
- paradox in the quality of care in centralization of pancreatic cancer surgery | BJS | Oxford Academic
- Centre Versus Surgeon Volume in Pancreatic Surgery
- ERAS enables safe ≤ 100-hour discharge after pancreatoduodenectomy: a multicenter cohort study | Langenbeck's Archives of Surgery | Springer Nature Link
- Enhanced recovery after surgery in pancreatic surgery: a comparative systematic review of global practices, compliance variation, and clinical outcomes - ScienceDirect
- Guidelines News | ESMO
- National Comprehensive Cancer Network® (NCCN®) | LinkedIn
- Guideline Topic Priorities - ASCO
- Contemporary Multidisciplinary Treatment of Borderline-Resectable and Locally Advanced Pancreatic Adenocarcinoma | American Society of Clinical Oncology Educational Book
- Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
- Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial - PubMed
- Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial.
- Frontiers | Limited benefits of neoadjuvant therapy on R0 resection rate and overall survival in patients with resectable or locally advanced PDAC in randomized controlled trials
Based on findings from:
In memory of professor Paolo Pederzoli
Roberto Salvia. Updates In Surgery, 2026.
https://link.springer.com/article/10.1007/s13304-026-02871-9
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.